Health Care • Ophthalmic Goods
$16.64 ▲ +1.18
(+7.63%)
MKT CAP: $1.32B • VOL: 2.48M
52W L $15 52W H $30
ROARABLE / RQD
C+ • 68/100
PIOTROSKI
7 / 9
EYE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-01-03 | FY 2024
FILED 2024-12-28 | FY 2023
FILED 2023-12-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.99B | $1.82B | $1.76B |
| YoY Revenue Growth % | +9.0% | +3.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $58.8M | -$10.4M | $24.5M |
| Operating Margin % | 3.0% | -0.6% | 1.4% |
| Net Income (GAAP) | $29.6M | -$28.5M | -$65.9M |
| EBITDA (Normalized) | $117.1M | $66.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $146.3M | $133.6M | $173.0M |
| Capital Expenditures (CapEx) | $72.8M | $95.5M | — |
| Free Cash Flow (FCF) | $73.5M | $38.1M | $173.0M |
| FCF Margin % | 3.7% | 2.1% | 9.9% |
| Return on Invested Capital (ROIC %) | 4.4% | -0.8% | — |
| Cash & Short-Term Equivalents | $38.7M | $73.9M | — |
| Total Debt (Short + Long Term) | $223.2M | $239.1M | — |
| Total Stockholders' Equity | $869.5M | $816.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EYE.